BR112015022084A2 - composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol - Google Patents

composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol

Info

Publication number
BR112015022084A2
BR112015022084A2 BR112015022084A BR112015022084A BR112015022084A2 BR 112015022084 A2 BR112015022084 A2 BR 112015022084A2 BR 112015022084 A BR112015022084 A BR 112015022084A BR 112015022084 A BR112015022084 A BR 112015022084A BR 112015022084 A2 BR112015022084 A2 BR 112015022084A2
Authority
BR
Brazil
Prior art keywords
dipyridamole
compositions
eye disorders
treating eye
effective amount
Prior art date
Application number
BR112015022084A
Other languages
English (en)
Portuguese (pt)
Inventor
Rogosnitzky Moshe
Original Assignee
Remedeye Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedeye Inc filed Critical Remedeye Inc
Publication of BR112015022084A2 publication Critical patent/BR112015022084A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112015022084A 2013-03-12 2014-03-11 composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol BR112015022084A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compounds for use in ocular disorders using dipyridamole
PCT/IB2014/059645 WO2014141079A1 (fr) 2013-03-12 2014-03-11 Compositions destinées à être utilisées en traitement de troubles oculaires à l'aide de dipyridamole

Publications (1)

Publication Number Publication Date
BR112015022084A2 true BR112015022084A2 (pt) 2017-07-18

Family

ID=48916407

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022084A BR112015022084A2 (pt) 2013-03-12 2014-03-11 composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol

Country Status (14)

Country Link
EP (1) EP2968328A4 (fr)
JP (1) JP6820658B2 (fr)
KR (2) KR20210010638A (fr)
CN (1) CN105188702B (fr)
AU (1) AU2014229371B2 (fr)
BR (1) BR112015022084A2 (fr)
CA (1) CA2905594A1 (fr)
CL (1) CL2015002627A1 (fr)
EA (1) EA035966B1 (fr)
IL (1) IL225179A (fr)
MX (1) MX2015012716A (fr)
MY (1) MY182591A (fr)
SG (2) SG11201507092QA (fr)
WO (1) WO2014141079A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180015090A1 (en) * 2015-01-28 2018-01-18 Realinn Life Science Limited COMPOUNDS FOR ENHANCING PPARy EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001806A1 (fr) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Formulations de dipyridamole stables avec des impuretés réduites
WO2021001805A1 (fr) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Formulations de dipyridamole stables et leurs procédés de préparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (ja) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd ジピリダモールを必須成分とする眼圧降下剤
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
RU2008122978A (ru) * 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
WO2010056710A1 (fr) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions et procédés pour traiter des maladies ophtalmiques
EP2363126A1 (fr) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprenant une L-carnitine en tant que principe actif en combinaison avec le glucoside de l'hydroxykynurénine, pour la prévention et/ou le traitement de pathologies de l'oeil dues au rayonnement ultraviolet

Also Published As

Publication number Publication date
CL2015002627A1 (es) 2016-03-11
KR20150126021A (ko) 2015-11-10
IL225179A0 (en) 2013-06-27
MX2015012716A (es) 2016-07-06
MY182591A (en) 2021-01-26
CA2905594A1 (fr) 2014-09-18
KR20210010638A (ko) 2021-01-27
SG11201507092QA (en) 2015-10-29
IL225179A (en) 2017-01-31
EA035966B1 (ru) 2020-09-07
WO2014141079A1 (fr) 2014-09-18
EP2968328A4 (fr) 2016-11-23
EP2968328A1 (fr) 2016-01-20
AU2014229371B2 (en) 2018-05-10
JP2016514123A (ja) 2016-05-19
SG10201706937UA (en) 2017-09-28
AU2014229371A1 (en) 2015-10-29
JP6820658B2 (ja) 2021-01-27
EA201591653A1 (ru) 2017-05-31
CN105188702B (zh) 2019-03-26
CN105188702A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112015020302A2 (pt) derivado de pirazol
CU20130069A7 (es) Derivados de 2,3-dihidroimidazo[1,2-c] quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermeddes asociadas a la angiogénesis
WO2015157559A3 (fr) Saxitoxines 10',11'-modifiées pour le traitement de la douleur
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015022650A2 (pt) inibidores de cinase induzível por sal macrocíclico
BR112015027440A2 (pt) DERIVADO DE [1,2,4]TRIAZOL[4,3-a]PIRIDINA, MÉTODO DE PREPA-RAÇÃO OU APLICAÇÃO MÉDICA DO DERIVADO
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112015022084A2 (pt) composições para uso em tratamento de distúrbios oculares com o uso de dipiridamol
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
RU2015112121A (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
BR112015014261A8 (pt) composto de danazol, seu uso e formulação farmacêutica compreendendo este
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
BR112015019524A2 (pt) tratamento de combinação
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
BR112015003733A2 (pt) composições de liberação estendida de um nitrato de aminoalquila

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: O.D. OCULAR DISCOVERY LTD. (IL)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI